title: Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study.
authors.forename: S
authors.initials: S
authors.lastname: Agelaki
authors.forename: E
authors.initials: E
authors.lastname: Karyda
authors.forename: Ch
authors.initials: Ch
authors.lastname: Kouroussis
authors.forename: A
authors.initials: A
authors.lastname: Ardavanis
authors.forename: K
authors.initials: K
authors.lastname: Kalbakis
authors.forename: K
authors.initials: K
authors.lastname: Malas
authors.forename: N
authors.initials: N
authors.lastname: Malamos
authors.forename: A
authors.initials: A
authors.lastname: Alexopoulos
authors.forename: E
authors.initials: E
authors.lastname: Tselepatiotis
authors.forename: V
authors.initials: V
authors.lastname: Georgoulias
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D003841:Deoxycytidine; D000077146:Irinotecan; D002166:Camptothecin; D000093542:Gemcitabine